Latest Galectin Therapeutics Inc (GALT) Headlines
Fatty Liver Disease Should Keep Stocks Moving In 2014
at Investor's Business Daily - Fri Mar 07, 4:02PM CST
One of the hottest research fields in biotech is for a disease most people have never heard of. But as data on potential treatments roll out this year, it's bound to become a lot more famous on Wall Street. Non-alcoholic steatohepatitis, or NASH,...
Galectin Therapeutic Has Returned 98.8% Since SmarTrend Recommendation (GALT)
Comtex SmarTrend(R) - Fri Mar 07, 9:08AM CST
SmarTrend identified an Uptrend for Galectin Therapeutic (NASDAQ:GALT) on November 25th, 2013 at $8.00. In approximately 3 months, Galectin Therapeutic has returned 98.75% as of today's recent price of $15.90.
Today's Biggest Stories in Biotech: Galectin Therapeutics Inc, Merrimack Pharmaceuticals and Nektar
George Budwell, The Motley Fool - Motley Fool - Thu Feb 27, 8:27AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Galectin Therapeutics wins US patent for GR-MD-02
M2 - Thu Feb 27, 5:22AM CST
US-based therapeutics company Galectin Therapeutics (NasdaqCM:GALT) disclosed on Wednesday the receipt of the patent for its application titled "Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease" in the US.
Galectin Therapeutics Secures U.S. Patent for its Proprietary Galectin Inhibitor GR-MD-02 in Fatty Liver Disease
GlobeNewswire - Wed Feb 26, 7:42AM CST
Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the U.S. Patent and Trademark Office issued patent number 8,658,787 to the Company for its application titled "Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease." The patent covers the Company's carbohydrate-based galectin inhibitor compound GR-MD-02 for use in patients with fatty liver disease with or without fibrosis or cirrhosis, providing patent protection through 2031.
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 25, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Galectin Therapeutic Shares Up 109.5% Since SmarTrend's Buy Recommendation (GALT)
Comtex SmarTrend(R) - Tue Feb 25, 9:41AM CST
SmarTrend identified an Uptrend for Galectin Therapeutic (NASDAQ:GALT) on November 25th, 2013 at $8.00. In approximately 3 months, Galectin Therapeutic has returned 109.50% as of today's recent price of $16.76.
5 Biotech Stocks to Trade for Breakouts
at The Street - Mon Feb 24, 1:08PM CST
Here's a technical look at five potentially explosive biotech stock plays.
Galectin Therapeutics Presents at JMP Securities' Nonalcoholic Steatohepatitis (NASH) Workshop
GlobeNewswire - Mon Feb 24, 9:42AM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company will present at the Nonalcoholic Steatohepatitis (NASH) Workshop hosted by JMP Securities on Thursday, February 27, 2014 in New York, NY. NASH, a progressive liver disease caused by the accumulation of fat in the liver leading to inflammation and fibrosis, is estimated to affect nine to 15 million people, including children, in the United States.
90.8% Return Seen to Date on SmarTrend Galectin Therapeutic Call (GALT)
Comtex SmarTrend(R) - Tue Feb 18, 9:06AM CST
SmarTrend identified an Uptrend for Galectin Therapeutic (NASDAQ:GALT) on November 25th, 2013 at $8.00. In approximately 3 months, Galectin Therapeutic has returned 90.75% as of today's recent price of $15.26.
Galectin Therapeutics Leaps Ahead with SBH Sciences Partnership
ACCESSWIRE - Thu Feb 13, 10:02AM CST
A growing body of research on galectins is demonstrating the important role that this family of carbohydrate-binding proteins plays in T-cell survival, fibrosis of organs, allergies, deadly diseases like cancer, regulation of many immune responses and much more. Only defined about two decades ago, 15 different mammalian galectins have now been identified, with overexpression of specific galectins implicated in a variety of diseases. The potential of this emerging science is tremendous, to say the least, to help bridge gaps in a broad range of deadly or debilitating disorders with great unmet medical need.
Galectin Therapeutics CEO Serves on Cancer Immunotherapy Panel at BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 13, 7:00AM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., Chief Executive Officer, President and Chief Medical Officer of Galectin Therapeutics, served on a panel titled "Keeping an I on Oncology: The ASCO Immunotherapy Preview" at the 16 Annual BIO CEO & Investor Conference. The panel was held February 11, 2014, in New York City.
3 Biotech Stocks Rising on Big Volume
at The Street - Tue Feb 11, 5:00AM CST
Keep these biotech stocks trading on unusual volume on your radar.
Shares of GALT Up 86.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 10, 9:10AM CST
SmarTrend identified an Uptrend for Galectin Therapeutic (NASDAQ:GALT) on November 25th, 2013 at $8.00. In approximately 3 months, Galectin Therapeutic has returned 86.25% as of today's recent price of $14.90.
Galectin Therapeutics to Present at 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Wed Feb 05, 7:15AM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company will present at the 16 Annual BIO CEO & Investor Conference, to be held February 10-11, 2014, at the Waldorf Astoria Hotel in New York City. The conference is hosted by the Biotechnology Industry Organization and is the largest independent investor conference focused on established and emerging publicly traded and select private biotech companies.
Galectin Therapeutics and Providence Portland Medical Center Receive OK From FDA to Proceed With Phase 1B Clinical Trial in Metastatic Melanoma
GlobeNewswire - Mon Feb 03, 10:30AM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the U.S. Food and Drug Administration (FDA) has agreed that a Phase 1B clinical trial of the galectin inhibitor GR-MD-02 in combination with Yervoy(R) (ipilimumab) in patients with metastatic melanoma may proceed. Providence Portland Medical Center, a leader in immunotherapy research and translational clinical trials in melanoma and other cancers, filed the IND in late December 2013.
Galectin Therapeutic Has Returned 71.4% Since SmarTrend Recommendation (GALT)
Comtex SmarTrend(R) - Fri Jan 31, 4:47PM CST
SmarTrend identified an Uptrend for Galectin Therapeutic (NASDAQ:GALT) on November 25th, 2013 at $8.00. In approximately 2 months, Galectin Therapeutic has returned 71.38% as of today's recent price of $13.71.
Galectin Therapeutics Inc & SBH Sciences Inc partnership establishes Galectin Sciences LLC for development of small molecule inhibitors of galectin-3
M2 - Tue Jan 28, 6:22AM CST
Therapeutic company Galectin Therapeutics Inc (NasdaqCM:GALT) and SBH Sciences Inc on Monday jointly reported the formation of collaborative joint venture to research and develop small organic molecule inhibitors of galectin-3 for oral administration, called Galectin Sciences LLC.
Galectin Therapeutics Inc. and SBH Sciences, Inc. Announce the Formation of Galectin Sciences, LLC, a Collaborative Venture to Research and Develop Galectin Inhibitors for Oral Administration
GlobeNewswire - Mon Jan 27, 7:15AM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, and SBH Sciences, Inc., a world leader in cell-based assays to measure biological activity and developer of cytokines, growth factors, biologics and monoclonal antibodies, jointly announce the establishment and formation of Galectin Sciences, LLC, a collaborative venture to research and develop small organic molecule inhibitors of galectin-3 for oral administration.
Fatty Liver Disease Should Keep Stocks Moving In 2014
at Investor's Business Daily - Fri Mar 07, 4:02PM CST
One of the hottest research fields in biotech is for a disease most people have never heard of. But as data on potential treatments roll out this year, it's bound to become a lot more famous on Wall Street. Non-alcoholic steatohepatitis, or NASH,...
Galectin Therapeutic Has Returned 98.8% Since SmarTrend Recommendation (GALT)
Comtex SmarTrend(R) - Fri Mar 07, 9:08AM CST
SmarTrend identified an Uptrend for Galectin Therapeutic (NASDAQ:GALT) on November 25th, 2013 at $8.00. In approximately 3 months, Galectin Therapeutic has returned 98.75% as of today's recent price of $15.90.
Today's Biggest Stories in Biotech: Galectin Therapeutics Inc, Merrimack Pharmaceuticals and Nektar
George Budwell, The Motley Fool - Motley Fool - Thu Feb 27, 8:27AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Galectin Therapeutics wins US patent for GR-MD-02
M2 - Thu Feb 27, 5:22AM CST
US-based therapeutics company Galectin Therapeutics (NasdaqCM:GALT) disclosed on Wednesday the receipt of the patent for its application titled "Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease" in the US.
Galectin Therapeutics Secures U.S. Patent for its Proprietary Galectin Inhibitor GR-MD-02 in Fatty Liver Disease
GlobeNewswire - Wed Feb 26, 7:42AM CST
Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the U.S. Patent and Trademark Office issued patent number 8,658,787 to the Company for its application titled "Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease." The patent covers the Company's carbohydrate-based galectin inhibitor compound GR-MD-02 for use in patients with fatty liver disease with or without fibrosis or cirrhosis, providing patent protection through 2031.
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 25, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Galectin Therapeutic Shares Up 109.5% Since SmarTrend's Buy Recommendation (GALT)
Comtex SmarTrend(R) - Tue Feb 25, 9:41AM CST
SmarTrend identified an Uptrend for Galectin Therapeutic (NASDAQ:GALT) on November 25th, 2013 at $8.00. In approximately 3 months, Galectin Therapeutic has returned 109.50% as of today's recent price of $16.76.
5 Biotech Stocks to Trade for Breakouts
at The Street - Mon Feb 24, 1:08PM CST
Here's a technical look at five potentially explosive biotech stock plays.
Galectin Therapeutics Presents at JMP Securities' Nonalcoholic Steatohepatitis (NASH) Workshop
GlobeNewswire - Mon Feb 24, 9:42AM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company will present at the Nonalcoholic Steatohepatitis (NASH) Workshop hosted by JMP Securities on Thursday, February 27, 2014 in New York, NY. NASH, a progressive liver disease caused by the accumulation of fat in the liver leading to inflammation and fibrosis, is estimated to affect nine to 15 million people, including children, in the United States.
90.8% Return Seen to Date on SmarTrend Galectin Therapeutic Call (GALT)
Comtex SmarTrend(R) - Tue Feb 18, 9:06AM CST
SmarTrend identified an Uptrend for Galectin Therapeutic (NASDAQ:GALT) on November 25th, 2013 at $8.00. In approximately 3 months, Galectin Therapeutic has returned 90.75% as of today's recent price of $15.26.
Galectin Therapeutics Leaps Ahead with SBH Sciences Partnership
ACCESSWIRE - Thu Feb 13, 10:02AM CST
A growing body of research on galectins is demonstrating the important role that this family of carbohydrate-binding proteins plays in T-cell survival, fibrosis of organs, allergies, deadly diseases like cancer, regulation of many immune responses and much more. Only defined about two decades ago, 15 different mammalian galectins have now been identified, with overexpression of specific galectins implicated in a variety of diseases. The potential of this emerging science is tremendous, to say the least, to help bridge gaps in a broad range of deadly or debilitating disorders with great unmet medical need.
Galectin Therapeutics CEO Serves on Cancer Immunotherapy Panel at BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 13, 7:00AM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., Chief Executive Officer, President and Chief Medical Officer of Galectin Therapeutics, served on a panel titled "Keeping an I on Oncology: The ASCO Immunotherapy Preview" at the 16 Annual BIO CEO & Investor Conference. The panel was held February 11, 2014, in New York City.
3 Biotech Stocks Rising on Big Volume
at The Street - Tue Feb 11, 5:00AM CST
Keep these biotech stocks trading on unusual volume on your radar.
Shares of GALT Up 86.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 10, 9:10AM CST
SmarTrend identified an Uptrend for Galectin Therapeutic (NASDAQ:GALT) on November 25th, 2013 at $8.00. In approximately 3 months, Galectin Therapeutic has returned 86.25% as of today's recent price of $14.90.
Galectin Therapeutics to Present at 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Wed Feb 05, 7:15AM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company will present at the 16 Annual BIO CEO & Investor Conference, to be held February 10-11, 2014, at the Waldorf Astoria Hotel in New York City. The conference is hosted by the Biotechnology Industry Organization and is the largest independent investor conference focused on established and emerging publicly traded and select private biotech companies.
Galectin Therapeutics and Providence Portland Medical Center Receive OK From FDA to Proceed With Phase 1B Clinical Trial in Metastatic Melanoma
GlobeNewswire - Mon Feb 03, 10:30AM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the U.S. Food and Drug Administration (FDA) has agreed that a Phase 1B clinical trial of the galectin inhibitor GR-MD-02 in combination with Yervoy(R) (ipilimumab) in patients with metastatic melanoma may proceed. Providence Portland Medical Center, a leader in immunotherapy research and translational clinical trials in melanoma and other cancers, filed the IND in late December 2013.
Galectin Therapeutic Has Returned 71.4% Since SmarTrend Recommendation (GALT)
Comtex SmarTrend(R) - Fri Jan 31, 4:47PM CST
SmarTrend identified an Uptrend for Galectin Therapeutic (NASDAQ:GALT) on November 25th, 2013 at $8.00. In approximately 2 months, Galectin Therapeutic has returned 71.38% as of today's recent price of $13.71.
Galectin Therapeutics Inc & SBH Sciences Inc partnership establishes Galectin Sciences LLC for development of small molecule inhibitors of galectin-3
M2 - Tue Jan 28, 6:22AM CST
Therapeutic company Galectin Therapeutics Inc (NasdaqCM:GALT) and SBH Sciences Inc on Monday jointly reported the formation of collaborative joint venture to research and develop small organic molecule inhibitors of galectin-3 for oral administration, called Galectin Sciences LLC.
Galectin Therapeutics Inc. and SBH Sciences, Inc. Announce the Formation of Galectin Sciences, LLC, a Collaborative Venture to Research and Develop Galectin Inhibitors for Oral Administration
GlobeNewswire - Mon Jan 27, 7:15AM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, and SBH Sciences, Inc., a world leader in cell-based assays to measure biological activity and developer of cytokines, growth factors, biologics and monoclonal antibodies, jointly announce the establishment and formation of Galectin Sciences, LLC, a collaborative venture to research and develop small organic molecule inhibitors of galectin-3 for oral administration.
